RxDoctor Payments Data

Johnna Hobbs, OD

Corneal and Contact Management · Bloomington, MNNPI 1437224276

Payments from drug & device makers

What this record shows

Biotissue Holdings Inc. accounts for 73.6% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2023 at $1,135 and has fallen 95.4% since, to $53 in 2025.

$1,625in general payments, 2019–2025

Across 15 payments — averaging $108.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotissue Holdings Inc.$1K
  • Sight Sciences, Inc.$150
  • Dompe US, Inc.$112
  • Alcon$76
  • Oyster Point Pharma, Inc.$32
  • Harrow Eye, LLC$30
  • plus $30 from 1 others

What the payments were for

  • Travel & lodging$95959%
  • Food & beverage$66641%

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,625 in reported general payments places this provider in the 75th percentile of 30 corneal and contact management providers in Minnesota.

See all corneal and contact management providers in Minnesota

Medicare billing

Part B allowed, 2024
$90,934
Medicare patients
550
Services billed
1,208

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine198$264,320
XiidraLifitegrast52$69,928
Cyclosporine92$58,106
LumiganBimatoprost58$27,106
XdemvyLotilaner14$26,448
TyrvayaVarenicline Tartrate13$16,833
MieboPerfluorohexyloctane/Pf13$13,961
RhopressaNetarsudil Mesylate20$11,384
Latanoprost474$9,595
RocklatanNetarsudil Mesylat/Latanoprost12$9,583
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol55$8,403
VyzultaLatanoprostene Bunod15$7,769
Prednisolone Acetate157$5,840
Loteprednol Etabonate22$5,419
SimbrinzaBrinzolamide/Brimonidine Tart21$5,387

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Oyster Point Pharma, Inc.Tyrvaya$32$16,83313 claims
AlconSimbrinza$76$5,38721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 30 corneal and contact management providers in Minnesota.

Other corneal and contact management in Bloomington

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →